| Indicators | Browse All

Foghorn Therapeutics Inc. (FHTX)

Healthcare | Biotechnology | Watertown, United States | NasdaqGM
6.00 USD -0.22 (-3.537%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 6.00

Short-term:★★⯪☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 1:31 a.m. EDT

The long-term investment case is severely compromised by a four-year cumulative decline of nearly 48%, driven by a brutal 50% drop in 2023 followed by another 26% fall last year. Despite a recent surge in share price, the underlying business fundamentals remain broken, evidenced by negative gross margins, negative operating cash flow, and a forward P/E that indicates no expected earnings. The company is burning through cash rapidly with no revenue to offset the burn, and the balance sheet shows negative book value. While the short-term price has rallied off lows, the lack of a dividend, the massive cash burn, and the deteriorating operational metrics suggest this is a speculative gamble on a turnaround rather than a sound investment. The options market confirms this fear, with traders buying deep protection rather than betting on a recovery.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.261541
AutoETS0.277033
AutoARIMA0.279782
AutoTheta0.287353

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 36%
H-stat 3.36
Ljung-Box p 0.000
Jarque-Bera p 0.455
Excess Kurtosis -0.89
Attribute Value
Sector Healthcare
Revenue per Share 0.552
Market Cap 356,311,904
Forward P/E -5.50
Beta 2.84
Profit Margins -175.78%
Website https://foghorntx.com

As of Aug. 22, 2026, 1:31 a.m. EDT: Speculators are heavily positioned for downside protection, with open interest concentrated entirely in out-of-the-money puts at the $2.50 strike, while call activity is negligible and skewed toward deep out-of-the-money strikes. Implied volatility is elevated for puts relative to calls, suggesting a market consensus focused on survival rather than upside expansion.


Info Dump

Attribute Value
52 Week Change 0.17803025
Address1 99 Coolidge Avenue
Address2 Suite 500
All Time High 28.265
All Time Low 2.7
Ask 6.1
Ask Size 2
Audit Risk 4
Average Analyst Rating 1.1 - Strong Buy
Average Daily Volume10 Day 417,130
Average Daily Volume3 Month 303,193
Average Volume 303,193
Average Volume10Days 417,130
Beta 2.835
Bid 3.55
Bid Size 2
Board Risk 7
Book Value -1.38
City Watertown
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 7
Country United States
Crypto Tradeable 0
Currency USD
Current Price 6.0
Current Ratio 3.362
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 6.24
Day Low 5.96
Display Name Foghorn Therapeutics
Earnings Timestamp 1,786,019,400
Earnings Timestamp End 1,793,881,800
Earnings Timestamp Start 1,793,881,800
Ebitda -66,353,000
Ebitda Margins -1.8060601
Enterprise To Ebitda -3.691
Enterprise To Revenue 6.666
Enterprise Value 244,896,656
Eps Current Year -0.87
Eps Forward -1.09125
Eps Trailing Twelve Months -0.99
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 5.478
Fifty Day Average Change 0.52199984
Fifty Day Average Change Percent 0.09529022
Fifty Two Week Change Percent 17.803024
Fifty Two Week High 7.61
Fifty Two Week High Change -1.6100001
Fifty Two Week High Change Percent -0.21156375
Fifty Two Week Low 3.27
Fifty Two Week Low Change 2.73
Fifty Two Week Low Change Percent 0.8348624
Fifty Two Week Range 3.27 - 7.61
Financial Currency USD
First Trade Date Milliseconds 1,603,459,800,000
Float Shares 28,080,940
Forward Eps -1.09125
Forward P E -5.498282
Free Cashflow -51,954,876
Full Exchange Name NasdaqGM
Full Time Employees 106
Fullday Change -0.22
Fullday Change Percent -3.53697
Fullday Price 6.0
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,785,542,400
Gross Margins -1.14568
Gross Profits -42,091,000
Has Pre Post Market Data 1
Held Percent Insiders 0.14135
Held Percent Institutions 0.76702005
Implied Shares Outstanding 59,385,315
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,020-10-23
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Long Name Foghorn Therapeutics Inc.
Market us_market
Market Cap 356,311,904
Market State CLOSED
Max Age 86,400
Message Board Id finmb_538076136
Most Recent Quarter 1,782,777,600
Net Income To Common -64,579,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 368,782,806
Number Of Analyst Opinions 9
Open 6.17
Operating Cashflow -84,241,000
Operating Margins -0.54785
Overall Risk 6
Payout Ratio 0.0
Phone 617 586 3100
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 6.0
Post Market Time 1,787,959,806
Previous Close 6.22
Price Eps Current Year -6.8965516
Price Hint 2
Price To Book -4.347826
Price To Sales Trailing12 Months 9.698465
Profit Margins -1.75778
Quick Ratio 3.313
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.1
Region US
Regular Market Change -0.22
Regular Market Change Percent -3.53697
Regular Market Day High 6.24
Regular Market Day Low 5.96
Regular Market Day Range 5.96 - 6.24
Regular Market Open 6.17
Regular Market Previous Close 6.22
Regular Market Price 6.0
Regular Market Time 1,787,947,201
Regular Market Volume 370,706
Return On Assets -0.19923
Revenue Growth 1.127
Revenue Per Share 0.552
Sand P52 Week Change 0.1966995
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 6
Shares Outstanding 59,385,315
Shares Percent Shares Out 0.0301
Shares Short 1,786,939
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 1,535,862
Short Name Foghorn Therapeutics Inc.
Short Percent Of Float 0.0547
Short Ratio 7.73
Source Interval 15
State MA
Symbol FHTX
Target High Price 14.0
Target Low Price 9.0
Target Mean Price 11.44444
Target Median Price 12.0
Total Cash 167,582,000
Total Cash Per Share 2.822
Total Debt 43,102,000
Total Revenue 36,739,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.99
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 5.081825
Two Hundred Day Average Change 0.9181752
Two Hundred Day Average Change Percent 0.18067825
Type Disp Equity
Volume 370,706
Website https://foghorntx.com
Zip 2,472